Pancreatic Cancer Research

ResearcherShizuoka General HospitalActive in the last 2 years

Shinya Kawaguchi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-7038-7955; OpenAlex author ID A5061063490. Sources: OpenAlex.

Their work

Papers
19 (first author 3, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 5 papers · 2026: 5 papers

Papers 19

  1. Clinical and imaging differences between pancreatic carcinoma in situ and T1a/T1b pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00261-026-05453-w↗
  2. Intratumoral perforation following endoscopic duodenal stent placement for pancreatic cancer with gastric outlet obstruction. Co-author DOI 10.1007/s12328-026-02311-6↗
  3. Identifying risk factors for pancreatic cancer in a large Japanese cohort using an insurance and health check-up database. Co-author DOI 10.1016/j.pan.2026.04.012↗
  4. Groove area involvement predicts post-ERCP pancreatitis after 8-mm fully-covered metal stent placement in resectable pancreatic cancer. Co-author DOI 10.1055/a-2803-4865↗
  5. Neoadjuvant Chemotherapy after Plasmapheresis in Borderline Resectable Pancreatic Cancer: A Case Report. Co-author DOI 10.1159/000553338↗
  6. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of trea… Co-author DOI 10.1007/s00535-024-02186-9↗
  7. Correction: Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probabi… Co-author DOI 10.1007/s00535-025-02215-1↗
  8. Repeated pancreatic juice cytology via endoscopic nasopancreatic drainage catheter combined with clinical findings improves diagnostic ability for malignant ca… Last author DOI 10.1016/j.pan.2024.11.022↗
  9. Assessment of safety and patency of 7-mm covered metal stents for preoperative biliary drainage in pancreatic cancer: Prospective multicenter study. Co-author DOI 10.1055/a-2503-1995↗
  10. Minor papilla approach improves technical success of nasopancreatic drainage-based pancreatic juice cytology for early pancreatic cancer diagnosis. First author DOI 10.1055/a-2631-7957↗
  11. Pancreatic cancer risk in diabetic patients using the Japanese Regional Insurance Claims. Co-author DOI 10.1038/s41598-024-67505-9↗
  12. Intratumoral Air Bubbles and Hematemesis As Predictors of Pseudoaneurysm Rupture in Unresected Pancreatic Cancer. Last author DOI 10.2169/internalmedicine.0856-22↗
  13. Comparing the 14-mm uncovered and 10-mm covered metal stents in patients with distal biliary obstruction caused by unresectable pancreatic cancer: a multicente… Co-author DOI 10.1007/s00464-021-08342-z↗
  14. [A case of poorly differentiated pancreatic adenocarcinoma with spontaneous regression wherein retrospective rim enhancement findings were important for diagno… Co-author DOI 10.11405/nisshoshi.118.358↗
  15. Hepatic Arterial Infusion Chemotherapy for Liver Metastases Following Standard Chemotherapy for Pancreatic Cancer. First author DOI 10.2169/internalmedicine.5449-20↗
  16. Proposal for Endoscopic Ultrasonography Classification for Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics9010015↗
  17. Hereditary Pancreatitis Showing Numerous Cysts with Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0938-18↗
  18. Early Diagnosis to Improve the Poor Prognosis of Pancreatic Cancer. Co-author DOI 10.3390/cancers10020048↗
  19. A case of pancreatic cancer with severe vomiting treated by endoscopic ultrasound-guided celiac ganglia neurolysis. Co-author DOI 10.1007/s12328-017-0761-0↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tatsunori Satoh · 12 shared papers, 2018–2026 · strength 2.90
  2. Shinya Endo · 9 shared papers, 2021–2026 · strength 2.28
  3. Kazuya Ohno · 6 shared papers, 2024–2026 · strength 1.72
  4. Naofumi Shirane · 7 shared papers, 2017–2026 · strength 1.40
  5. Haruna Takahashi · 4 shared papers, 2025–2026 · strength 1.05
  6. Hideyuki Kanemoto · 5 shared papers, 2018–2026 · strength 0.99
  7. Yuichi Masui · 4 shared papers, 2018–2026 · strength 0.99
  8. Shuzo Terada · 7 shared papers, 2017–2023 · strength 0.92
  9. Asami Kawai · 3 shared papers, 2017–2026 · strength 0.62
  10. Hirotoshi Ishiwatari · 3 shared papers, 2022–2025 · strength 0.56
  11. Junya Sato · 3 shared papers, 2022–2025 · strength 0.56
  12. Masataka Kikuyama · 5 shared papers, 2017–2022 · strength 0.52
  13. Hiroshi Itoh · 2 shared papers, 2024–2026 · strength 0.52
  14. Takeshi Usui · 2 shared papers, 2024–2026 · strength 0.52
  15. Fumitaka Niiya · 2 shared papers, 2025 · strength 0.42
  16. Yoshihiro Uehara · 1 shared paper, 2026 · strength 0.36
  17. Akinori Asagi · 2 shared papers, 2025 · strength 0.32
  18. Yohei Kitano · 2 shared papers, 2025 · strength 0.32
  19. Nana Kimura · 2 shared papers, 2025 · strength 0.32
  20. Kunihiro Tsuji · 2 shared papers, 2025 · strength 0.32
  21. Kumiko Umemoto · 2 shared papers, 2025 · strength 0.32
  22. Takeshi Terashima · 2 shared papers, 2025 · strength 0.32
  23. Masayuki Ueno · 2 shared papers, 2025 · strength 0.32
  24. Satoshi Kobayashi · 2 shared papers, 2025 · strength 0.32
  25. Rei Suzuki · 2 shared papers, 2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.